Skip to content

Study · In vitro (cells) · 1999

5 results

Effects of the novel GH secretogogue, hexarelin on GH secretion and phosphatidylinositol hydrolysis by human pituitary somatotrophinomas in cell culture.

Liu Q, Lei T, Liu K, Bai X, Adams E

Journal of Tongji Medical University = Tong ji yi ke da xue xue bao1 Jan 1999Cited by 1 (Europe PMC)

PMID12840903 (opens in a new tab)DOI10.1007/bf02887743 (opens in a new tab)PepBankPUB-12840903
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In cultured human pituitary somatotrophinomas, hexarelin stimulated GH secretion in a dose-dependent manner, up to 4.6-fold.

    In plain wordsIn cells from human pituitary tumours, hexarelin raised growth hormone release as the dose went up, by as much as 4.6-fold.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH secretion
    Study

    humann: not reported in source

    Cultured human pituitary somatotrophinomas
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.01-100 nmol/LAs given in this study (human).

    Measurements

    Maximal GH stimulation
    4.6 fold
    Hexarelin 0.01-100 nmol/L

    Source sentences

    Summary
    Hexarelin (0.01-100 nmol/L) dose-dependently stimulated GH secretion up to 4.6-fold.
    1 context sentence
    Summary · context
    The effects of the novel GH-releasing hexapeptide, Hexarelin, on cultured human pituitary somatotrophinomas were investigated.
  2. 02LabIn vitro (cells)Activity measurement

    In cultured human pituitary somatotrophinomas, the maximal hexarelin effect on GH secretion occurred at 10 nmol/L.

    In plain wordsIn cells from human pituitary tumours, hexarelin had its largest effect on growth hormone release at 10 nmol/L.

    Peptide
    Hexarelin
    Outcome
    IncreaseConcentration with maximal GH effect
    Study

    humann: not reported in source

    Cultured human pituitary somatotrophinomas
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 nmol/LAs given in this study (human).

    Measurements

    Concentration of maximal effect
    10 nmol/L
    Hexarelin

    Source sentences

    Summary
    Maximal effects occurred with 10 nmol/L.
    1 context sentence
    Summary · context
    The effects of the novel GH-releasing hexapeptide, Hexarelin, on cultured human pituitary somatotrophinomas were investigated.
  3. 03LabIn vitro (cells)Activity measurement

    In cultured human pituitary somatotrophinomas, GHRP‑6 produced GH-releasing effects very similar to those of hexarelin.

    In plain wordsIn cells from human pituitary tumours, GHRP‑6 raised growth hormone release in a way very similar to hexarelin.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH secretion
    Study

    humann: not reported in source

    Cultured human pituitary somatotrophinomas
    Comparator
    Hexarelin
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These effects were very similar to those observed with GHRP-6.
    1 context sentence
    Summary · context
    The effects of the novel GH-releasing hexapeptide, Hexarelin, on cultured human pituitary somatotrophinomas were investigated.
  4. 04LabIn vitro (cells)Mechanism

    In cultured human pituitary somatotrophinomas, hexarelin increased the rate of phosphatidylinositol hydrolysis in a dose-dependent manner.

    In plain wordsIn cells from human pituitary tumours, hexarelin increased a signalling step (PI hydrolysis) as the dose went up.

    Peptide
    Hexarelin
    Outcome
    IncreasePhosphatidylinositol hydrolysis rate
    Study

    humann: not reported in source

    Cultured human pituitary somatotrophinomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The rate of phosphatidylinositol (PI) hydrolysis was markedly increased by Hexarelin in a dose-dependent manner.
    1 context sentence
    Summary · context
    The effects of the novel GH-releasing hexapeptide, Hexarelin, on cultured human pituitary somatotrophinomas were investigated.

Studies that did not test the peptide alone1

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 05LabNot a test of Hexarelin aloneIn vitro (cells)Mechanism

    In cultured human pituitary somatotrophinomas, the PKC inhibitor phloretin reduced the GH-releasing effect of hexarelin.

    In plain wordsIn cells from human pituitary tumours, a PKC blocker called phloretin reduced the growth hormone release caused by hexarelin.

    Peptide
    Hexarelin
    Outcome
    DecreaseHexarelin-stimulated GH secretion with the PKC inhibitor phloretin
    Study

    humann: not reported in source

    Cultured human pituitary somatotrophinomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    The effects of Hexarelin were reduced by phloretin, an inhibitor of protein kinase C (PKC).
    1 context sentence
    Summary · context
    The effects of the novel GH-releasing hexapeptide, Hexarelin, on cultured human pituitary somatotrophinomas were investigated.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 2

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.